1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
Lesovoy, D.M.
Bocharov, E.V.
Pustovalova, Y.E.
Bocharova, O.V.
Arseniev, A.S.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
NE
Biochim. Biophys. Acta
BBACAQ
0113
0006-3002
1858
1254
1261
10.1016/j.bbamem.2016.02.023
26903218
Alternative packing of EGFR transmembrane domain suggests that protein-lipid interactions underlie signal conduction across membrane.
2016
4733.849
Epidermal growth factor receptor
2.7.10.1
Transmembrane region residues 634-677
2
man
polymer
Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1
no
no
EGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKR
EGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKR
A,B
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
human
sample
EGFR, ERBB, ERBB1, HER1
9606
Homo sapiens
469008
Escherichia coli
BL21(DE3)pLysS
pGEMEX-1/(TRX-tmErbB1)
citation
citation_author
repository
Initial release
Data collection
Database references
1
0
2013-10-30
1
1
2019-06-26
_citation.country
_citation.journal_abbrev
_citation.journal_id_ASTM
_citation.journal_id_CSD
_citation.journal_id_ISSN
_citation.journal_volume
_citation.page_first
_citation.page_last
_citation.pdbx_database_id_DOI
_citation.pdbx_database_id_PubMed
_citation.title
_citation.year
BMRB
Y
RCSB
2012-10-24
REL
REL
REL
target function
200
20
2D 1H-15N HSQC
2D 1H-15N TROSY
2D 1H-13C constant time HSQC aliphatic
2D 1H-13C constant time HSQC aromatic
3D HNCO
3D HNCA
3D HN(CO)CA
3D HN(CA)CO
3D HNHA
3D HNHB
3D HCCH-TOCSY
3D 1H-15N(TROSY) NOESY
3D 1H-13C NOESY aliphatic
3D 1H-13C(constant time) NOESY aliphatic
15N,13C-F1-filtered/F3-edited-NOESY
15N,13C-F1-filtered/F3-edited-NOESY
0.75
mM
[U-99% 13C; U-99% 15N]
0.75
mM
90
mM
[U-99% 2H]
0.3
mM
6
mM
10
mM
20
mM
0.75
mM
[U-99% 13C; U-99% 15N]
0.75
mM
90
mM
[U-99% 2H]
0.3
mM
6
mM
10
mM
20
mM
50
5.0
ambient
313
K
simulated annealing, TORSION ANGLE DYNAMICS
1
fewest violations
0.75 mM [U-99% 13C; U-99% 15N] ErbB1tm, 0.75 mM ErbB1tm, 90 mM [U-99% 2H] DPC, 0.3 mM sodium azide, 6 mM TCEP, 10 mM citric acid, 20 mM Na2HPO4, 95% H2O/5% D2O
95% H2O/5% D2O
0.75 mM [U-99% 13C; U-99% 15N] ErbB1tm, 0.75 mM ErbB1tm, 90 mM [U-99% 2H] DPC, 0.3 mM sodium azide, 6 mM TCEP, 10 mM citric acid, 20 mM Na2HPO4, 99.9% D2O
99.9% D2O
Guntert, Mumenthaler and Wuthrich
structure solution
CYANA
3.0
Rochus Keller
chemical shift assignment
CARA
1.8.4
Wolfram Research
data analysis
Mathematica
Guntert, Mumenthaler and Wuthrich
refinement
CYANA
3.0
800
Bruker
Avance
Bruker Avance
600
Bruker
Avance
Bruker Avance
GLU
634
n
1
GLU
634
A
GLY
635
n
2
GLY
635
A
CYS
636
n
3
CYS
636
A
PRO
637
n
4
PRO
637
A
THR
638
n
5
THR
638
A
ASN
639
n
6
ASN
639
A
GLY
640
n
7
GLY
640
A
PRO
641
n
8
PRO
641
A
LYS
642
n
9
LYS
642
A
ILE
643
n
10
ILE
643
A
PRO
644
n
11
PRO
644
A
SER
645
n
12
SER
645
A
ILE
646
n
13
ILE
646
A
ALA
647
n
14
ALA
647
A
THR
648
n
15
THR
648
A
GLY
649
n
16
GLY
649
A
MET
650
n
17
MET
650
A
VAL
651
n
18
VAL
651
A
GLY
652
n
19
GLY
652
A
ALA
653
n
20
ALA
653
A
LEU
654
n
21
LEU
654
A
LEU
655
n
22
LEU
655
A
LEU
656
n
23
LEU
656
A
LEU
657
n
24
LEU
657
A
LEU
658
n
25
LEU
658
A
VAL
659
n
26
VAL
659
A
VAL
660
n
27
VAL
660
A
ALA
661
n
28
ALA
661
A
LEU
662
n
29
LEU
662
A
GLY
663
n
30
GLY
663
A
ILE
664
n
31
ILE
664
A
GLY
665
n
32
GLY
665
A
LEU
666
n
33
LEU
666
A
PHE
667
n
34
PHE
667
A
MET
668
n
35
MET
668
A
ARG
669
n
36
ARG
669
A
ARG
670
n
37
ARG
670
A
ARG
671
n
38
ARG
671
A
HIS
672
n
39
HIS
672
A
ILE
673
n
40
ILE
673
A
VAL
674
n
41
VAL
674
A
ARG
675
n
42
ARG
675
A
LYS
676
n
43
LYS
676
A
ARG
677
n
44
ARG
677
A
GLU
634
n
1
GLU
634
B
GLY
635
n
2
GLY
635
B
CYS
636
n
3
CYS
636
B
PRO
637
n
4
PRO
637
B
THR
638
n
5
THR
638
B
ASN
639
n
6
ASN
639
B
GLY
640
n
7
GLY
640
B
PRO
641
n
8
PRO
641
B
LYS
642
n
9
LYS
642
B
ILE
643
n
10
ILE
643
B
PRO
644
n
11
PRO
644
B
SER
645
n
12
SER
645
B
ILE
646
n
13
ILE
646
B
ALA
647
n
14
ALA
647
B
THR
648
n
15
THR
648
B
GLY
649
n
16
GLY
649
B
MET
650
n
17
MET
650
B
VAL
651
n
18
VAL
651
B
GLY
652
n
19
GLY
652
B
ALA
653
n
20
ALA
653
B
LEU
654
n
21
LEU
654
B
LEU
655
n
22
LEU
655
B
LEU
656
n
23
LEU
656
B
LEU
657
n
24
LEU
657
B
LEU
658
n
25
LEU
658
B
VAL
659
n
26
VAL
659
B
VAL
660
n
27
VAL
660
B
ALA
661
n
28
ALA
661
B
LEU
662
n
29
LEU
662
B
GLY
663
n
30
GLY
663
B
ILE
664
n
31
ILE
664
B
GLY
665
n
32
GLY
665
B
LEU
666
n
33
LEU
666
B
PHE
667
n
34
PHE
667
B
MET
668
n
35
MET
668
B
ARG
669
n
36
ARG
669
B
ARG
670
n
37
ARG
670
B
ARG
671
n
38
ARG
671
B
HIS
672
n
39
HIS
672
B
ILE
673
n
40
ILE
673
B
VAL
674
n
41
VAL
674
B
ARG
675
n
42
ARG
675
B
LYS
676
n
43
LYS
676
B
ARG
677
n
44
ARG
677
B
author_defined_assembly
2
dimeric
1072.1
-17.7
9931
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
1
A
CYS
636
-159.78
68.85
1
A
PRO
641
-69.71
98.56
1
A
ILE
643
-119.08
74.75
1
A
PRO
644
-69.72
-170.94
1
B
CYS
636
-150.27
73.40
1
B
ILE
643
-112.61
74.82
1
B
PRO
644
-69.81
-171.69
2
A
PRO
637
-69.75
76.84
2
A
PRO
644
-69.78
-166.09
2
B
CYS
636
54.23
73.17
2
B
PRO
637
-69.79
85.61
2
B
PRO
644
-69.74
-164.89
2
B
ILE
673
-58.34
98.29
3
A
CYS
636
-154.11
69.76
3
A
PRO
644
-69.78
-166.20
3
B
CYS
636
-152.58
70.52
3
B
PRO
637
-69.79
84.71
3
B
THR
638
37.81
42.58
3
B
PRO
641
-69.82
-172.36
3
B
ILE
643
-114.03
71.91
3
B
PRO
644
-69.77
-165.77
3
B
HIS
672
-59.41
106.02
4
A
PRO
644
-69.80
-165.73
4
A
VAL
674
62.41
63.52
4
B
CYS
636
-119.50
73.35
4
B
PRO
644
-69.76
-164.79
5
A
CYS
636
-171.60
73.95
5
A
PRO
637
-69.73
87.35
5
A
PRO
644
-69.74
-168.91
5
B
PRO
644
-69.72
-166.20
5
B
VAL
674
-60.37
97.73
6
A
PRO
644
-69.81
-168.21
6
A
HIS
672
-58.07
98.89
6
B
LYS
642
-164.62
-165.17
6
B
PRO
644
-69.71
-166.91
7
A
PRO
641
-69.81
-170.68
7
A
LYS
642
-172.23
146.66
7
A
ILE
643
54.05
74.15
7
A
PRO
644
-69.74
-169.02
7
A
ILE
673
-98.23
-69.91
7
B
PRO
641
-69.77
98.82
7
B
PRO
644
-69.86
-167.93
7
B
HIS
672
-97.87
-67.15
8
A
PRO
641
-69.77
88.54
8
A
ILE
643
50.26
70.31
8
A
PRO
644
-69.75
-165.45
8
B
CYS
636
59.68
70.25
8
B
PRO
644
-69.72
-165.98
9
A
CYS
636
-175.06
73.21
9
A
LYS
642
-171.13
142.39
9
A
ILE
643
-118.16
71.45
9
A
PRO
644
-69.82
-167.52
9
A
ILE
673
-62.24
98.17
9
A
ARG
675
-90.22
-67.47
9
A
LYS
676
-52.13
109.13
9
B
CYS
636
-118.42
68.07
9
B
PRO
644
-69.76
-169.10
10
A
CYS
636
-165.81
69.18
10
A
PRO
644
-69.77
-167.83
10
B
CYS
636
-155.92
70.39
10
B
THR
638
-160.63
87.95
10
B
PRO
644
-69.77
-165.57
11
A
CYS
636
55.63
74.42
11
A
THR
638
-170.08
87.47
11
A
PRO
644
-69.75
-167.25
11
B
PRO
637
-69.75
75.95
11
B
PRO
644
-69.84
-167.56
11
B
ARG
671
-80.19
-75.10
12
A
CYS
636
57.14
74.15
12
A
THR
638
-168.83
86.58
12
A
PRO
644
-69.78
-169.27
12
B
ILE
643
-115.44
69.99
12
B
PRO
644
-69.68
-169.58
12
B
ARG
670
48.74
27.94
13
A
CYS
636
59.39
71.19
13
A
PRO
644
-69.77
-168.80
13
B
PRO
637
-69.80
78.55
13
B
PRO
644
-69.76
-168.07
14
A
PRO
644
-69.80
-168.00
14
B
CYS
636
-161.51
73.41
14
B
THR
638
-160.41
79.77
14
B
PRO
644
-69.79
-169.07
15
A
CYS
636
53.04
71.12
15
A
THR
638
-164.62
92.28
15
A
PRO
644
-69.79
-167.17
15
B
CYS
636
-118.38
69.20
15
B
PRO
644
-69.81
-169.44
15
B
LYS
676
-54.68
172.53
16
A
PRO
644
-69.83
-167.97
16
A
HIS
672
-53.88
106.71
16
B
CYS
636
-154.86
73.73
16
B
PRO
637
-69.75
78.94
16
B
THR
638
37.37
43.42
16
B
ILE
643
61.01
69.75
16
B
PRO
644
-69.72
-166.60
16
B
LYS
676
-94.82
-68.56
17
A
CYS
636
-173.62
68.11
17
A
PRO
644
-69.72
-167.69
17
A
ARG
675
-81.43
-70.91
17
B
CYS
636
56.42
73.82
17
B
THR
638
-168.25
73.78
17
B
PRO
641
-69.79
-177.55
17
B
ILE
643
51.13
70.21
17
B
PRO
644
-69.72
-168.26
18
A
PRO
641
-69.74
78.03
18
A
ILE
643
51.12
73.00
18
A
PRO
644
-69.83
-169.29
18
B
CYS
636
-118.54
68.20
18
B
ILE
643
-113.24
74.25
18
B
PRO
644
-69.79
-168.38
18
B
HIS
672
-62.65
-170.94
19
A
CYS
636
-167.57
68.97
19
A
PRO
637
-69.70
80.13
19
A
THR
638
37.47
43.30
19
A
ILE
643
50.39
70.63
19
A
PRO
644
-69.78
-166.29
19
B
CYS
636
53.49
72.73
19
B
PRO
637
-69.82
92.27
19
B
PRO
644
-69.79
-168.34
19
B
ILE
673
-59.79
96.80
19
B
LYS
676
-58.04
178.99
20
A
PRO
637
-69.72
80.15
20
A
ILE
643
51.44
74.97
20
A
PRO
644
-69.73
-166.24
20
A
HIS
672
-51.69
103.17
20
B
PRO
637
-69.74
83.82
20
B
ILE
643
50.77
72.26
20
B
PRO
644
-69.72
-168.29
Epidermal growth factor receptor (E.C.2.7.10.1)
fewest violations, model 1
Homodimeric transmembrane domain of the human receptor tyrosine kinase ErbB1 (EGFR, HER1) in micelles
1
N
N
1
N
N
A
ILE
646
A
ILE
13
HELX_P
A
ARG
670
A
ARG
37
1
1
25
B
ILE
646
B
ILE
13
HELX_P
B
ARG
670
B
ARG
37
1
2
25
MEMBRANE PROTEIN
TRANSMEMBRANE DOMAIN, ERBB1, RECEPTOR, DIMERIZATION, TYROSINE KINASE, MEMBRANE PROTEIN
EGFR_HUMAN
UNP
1
634
P00533
EGCPTNGPKIPSIATGMVGALLLLLVVALGIGLFMRRRHIVRKR
634
677
2M0B
634
677
P00533
A
1
1
44
634
677
2M0B
634
677
P00533
B
1
1
44